Tdark VHLL von Hippel-Lindau-like protein

Protein Summary

Description

Functions as a dominant-negative VHL to serve as a protector of HIFalpha. Von Hippel-Lindau (VHL) tumor suppressor protein is a component of an E3 ubiquitin ligase complex that selectively ubiquitinates the alpha subunit of the hypoxia-inducible factor (HIF) transcription factor for proteasome-mediated degradation. Inactivation of VHL causes VHL disease and sporadic kidney cancer. This gene encodes a VHL homolog that lacks one of two key domains necessary for VHL function. This gene may contribute to the regulation of oxygen homeostasis and neovascularization during placenta development. This gene is intronless, and can also be interpreted as a retrotransposed pseudogene of the VHL locus located on chromosome 3. However, the protein is represented in this RefSeq due to evidence in PMID:14757845 that strongly suggests it is translated. The same publication also indicates that this protein binds HIF alpha but fails to recruit the E3 ubiquitin ligase complex, and it therefore functions as a dominant-negative VHL protein and a protector of HIF alpha. [provided by RefSeq, Jan 2010]

Uniprot Accession IDs

• Q6RSH7
• A1L4M4
• VHL-like protein

Gene Name

• VHLL

Ensembl ID

• ENST00000339922
• ENSP00000464258
• ENSG00000189030

Symbol

• VLP
• VLP
• VHLP

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
tissue	0.64
cell line	0.43
protein domain	0.41
tissue sample	0.35
interacting protein	0.31

Protein Classes

PANTHER Classes

Protein / Ligase / Von Hippel-lindau-like Protein

DTO Classes

Protein / Enzyme / Ligase / Von Hippel-lindau-like Protein

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 15.38   (req: < 5)

Gene RIFs: 1   (req: <= 3)

Antibodies: 50   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 15.38   (req: >= 5)

Gene RIFs: 1   (req: > 3)

Antibodies: 50   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 2

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0